{"id":"multistem","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Hypoxemia"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:19:23.275998","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MultiStem consists of allogeneic mesenchymal stem cells that are expanded and cryopreserved. These cells work through immunomodulatory and anti-inflammatory mechanisms, secreting bioactive factors that reduce inflammation, promote angiogenesis, and support tissue regeneration. The therapy is designed to address acute inflammatory conditions by restoring immune homeostasis and facilitating healing.","oneSentence":"MultiStem is a cell therapy derived from bone marrow-derived mesenchymal stem cells that modulates immune responses and promotes tissue repair.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:22.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute respiratory distress syndrome (ARDS)"},{"name":"Acute myocardial infarction"}]},"_fixedFields":["pubmed(39)"],"trialDetails":[{"nctId":"NCT04533464","phase":"PHASE2","title":"MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome","status":"RECRUITING","sponsor":"Healios K.K.","startDate":"2020-11-09","conditions":"Trauma, Adult Stem Cells","enrollment":156},{"nctId":"NCT03807804","phase":"PHASE2","title":"Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Healios K.K.","startDate":"2019-01-01","conditions":"Respiratory Distress Syndrome, Adult","enrollment":35},{"nctId":"NCT02961504","phase":"PHASE2, PHASE3","title":"Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements","status":"COMPLETED","sponsor":"Healios K.K.","startDate":"2017-11-15","conditions":"Stroke, Acute","enrollment":206},{"nctId":"NCT03545607","phase":"PHASE3","title":"MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study","status":"UNKNOWN","sponsor":"Healios K.K.","startDate":"2018-07-28","conditions":"Ischemic Stroke","enrollment":300},{"nctId":"NCT04367077","phase":"PHASE2, PHASE3","title":"MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)","status":"UNKNOWN","sponsor":"Healios K.K.","startDate":"2020-04-28","conditions":"ARDS","enrollment":400},{"nctId":"NCT02277613","phase":"PHASE2","title":"A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction","status":"TERMINATED","sponsor":"Healios K.K.","startDate":"2015-12","conditions":"Heart Attack, NSTEMI","enrollment":34},{"nctId":"NCT02611609","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Healios K.K.","startDate":"2016-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":36},{"nctId":"NCT01436487","phase":"PHASE2","title":"Study to Examine the Effects of MultiStem in Ischemic Stroke","status":"COMPLETED","sponsor":"Healios K.K.","startDate":"2011-10","conditions":"Ischemic Stroke","enrollment":134},{"nctId":"NCT00677222","phase":"PHASE1","title":"Safety Study of AMI MultiStem® to Treat Heart Attacks","status":"COMPLETED","sponsor":"Healios K.K.","startDate":"2008-05","conditions":"Acute Myocardial Infarction","enrollment":25},{"nctId":"NCT00677859","phase":"PHASE1","title":"Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia","status":"COMPLETED","sponsor":"Healios K.K.","startDate":"2008-07","conditions":"Hematologic Malignancies","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":39,"recentPublications":[{"date":"2026 Feb 6","pmid":"41607132","title":"Integrating transcriptomics and high-throughput gene editing uncovers shoot apical meristem regulators in Brassica napus.","journal":"Plant physiology"},{"date":"2025 Sep 19","pmid":"40894892","title":"SELEX identifies high-affinity RNA targets for chromatin-binding proteins PARP1 and MeCP2.","journal":"iScience"},{"date":"2025 Jul 16","pmid":"40547089","title":"Multi-STEM MePCR: a bisulfite-free, multiplex, highly sensitive and highly specific assay to measure DNA methylation.","journal":"Chemical science"},{"date":"2025 Sep","pmid":"40546115","title":"Lysosome-Featured Cell Aggregate-Released Extracellular Vesicles Regulate Iron Homeostasis and Alleviate Post-Irradiation Endothelial Ferroptosis for Mandibular Regeneration.","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"},{"date":"2024 Feb 1","pmid":"38227308","title":"Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial.","journal":"JAMA neurology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MultiStem®","genericName":"MultiStem®","companyName":"Healios K.K.","companyId":"healios-k-k","modality":"Biologic","firstApprovalDate":"","aiSummary":"MultiStem is a cell therapy derived from bone marrow-derived mesenchymal stem cells that modulates immune responses and promotes tissue repair. Used for Acute respiratory distress syndrome (ARDS), Acute myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}